Lijekovi koji modificiraju tijek bolesti - multipla skleroza

Šalinović, Hrvoje

prikaz prve stranice dokumenta Lijekovi koji modificiraju tijek bolesti - multipla skleroza

Download
PDF 2.05 MB

master's thesis

Lijekovi koji modificiraju tijek bolesti - multipla skleroza

Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry, 2016. urn:nbn:hr:163:179317

Šalinović, Hrvoje

University of Zagreb
Faculty of Pharmacy and Biochemistry
Department of pharmacology

Cite this document

APA 6th Edition

Šalinović, H. (2016). Lijekovi koji modificiraju tijek bolesti - multipla skleroza (Master's thesis). Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:179317

MLA 8th Edition

Šalinović, Hrvoje. "Lijekovi koji modificiraju tijek bolesti - multipla skleroza." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2016. https://urn.nsk.hr/urn:nbn:hr:163:179317

Chicago 17th Edition

Šalinović, Hrvoje. "Lijekovi koji modificiraju tijek bolesti - multipla skleroza." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2016. https://urn.nsk.hr/urn:nbn:hr:163:179317

Harvard

Šalinović, H. (2016). 'Lijekovi koji modificiraju tijek bolesti - multipla skleroza', Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, accessed 23 November 2024, https://urn.nsk.hr/urn:nbn:hr:163:179317

Vancouver

Šalinović H. Lijekovi koji modificiraju tijek bolesti - multipla skleroza [Master's thesis]. Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry; 2016 [cited 2024 November 23] Available at: https://urn.nsk.hr/urn:nbn:hr:163:179317

IEEE

H. Šalinović, "Lijekovi koji modificiraju tijek bolesti - multipla skleroza", Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, 2016. Available at: https://urn.nsk.hr/urn:nbn:hr:163:179317

Cite this item: https://urn.nsk.hr/urn:nbn:hr:163:179317

Please login to the repository to save this object to your list.

Metadata

Title	Lijekovi koji modificiraju tijek bolesti - multipla skleroza
Title (english)	Disease-modifying therapy - multiple sclerosis
Author	Hrvoje Šalinović
Mentor	Petra Turčić (mentor)
Committee member	Petra Turčić (predsjednik povjerenstva)
Committee member	Lidija Bach-Rojecky (član povjerenstva)
Committee member	Ivan Pepić (član povjerenstva)
Granter	University of Zagreb Faculty of Pharmacy and Biochemistry (Department of pharmacology) Zagreb
Defense date and country	2016-05-18, Croatia
Scientific / art field, discipline and subdiscipline	BIOMEDICINE AND HEALTHCARE Pharmacy Pharmacy
Abstract	Multipla skleroza je idiopatska, pretežno autoimuna, kronična, upalna, demijelinizirajuća bolest SŽS-a s genetskim i okolišnim učincima. Karakterizirana je demijelinizacijom SŽS i oštećenjem aksona. Novija istraživanja potvrđuju i zahvaćenost sive tvari. MS uzrokuje teškoće i onesposobljavanje, smanjenu mobilnost, probleme s vidom, probleme s koordinacijom, kognitivnu disfunkciju, umor i bol. Trenutno je odobreno 13 terapija koje modificiraju tijek bolesti multiple skleroze s različitim stupnjevima učinkovitosti za smanjenje rizika od relapsa i očuvanje neurološke funkcije. Novi pristup liječenju uglavnom uključuje monoklonska protutijela koja specifično ciljaju mete. Potencijalne nove mete su razne molekule povezane sa trenutnim spoznajama o uzročnicima ove bolesti. Predviđamo postupni napredak prema uistinu personaliziranoj terapiji MS kako se genomika i srodne discipline budu koristile za objašnjavanje i bolje razumijevanje individualne heterogenosti bolesti.
Abstract (english)	Multiple sclerosis is an idiopathic, putatively autoimmune, a chronic inflammatory demyelinating central nervous system disease with genetic and environmental effects. MS is characterized by CNS demyelination and axonal damage. Recent research has also highlighted an underappreciated involvement of gray matter. Multiple sclerosis causes bothersome or disabling physical symptoms involving mobility problems, vision problems, problems with coordination, cognitive dysfunction, fatigue, and pain. Currently, there are 13 approved MS DMTs with varying degrees of efficacy for reducing relapse risk and preserving neurological function. New treatment approaches mostly include monoclonal antibodies that target specific sites. Potential new targets are various molecules linked with what´s currently considered to be a cause of the disease development. We foresee gradual steps toward truly personalized medicine for MS as large-scale genomics and related disciplines are applied to explain the individual heterogeneity.
Keywords
Keywords (english)
Language	croatian
URN:NBN	urn:nbn:hr:163:179317
Study programme	Title: Pharmacy Study programme type: university Study level: integrated undergraduate and graduate Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
Type of resource	Text
File origin	Born digital
Access conditions	Open access
Terms of use
Repository	Repository of Faculty of Pharmacy and Biochemistry University of Zagreb
Created on	2016-06-08 09:51:47